Pliant Therapeutics Inc. Common Stock (PLRX)
Stock · NASDAQ · Health Care
$0.9027as of 10/16/2026
Price chart
Active signals
PLRX Signal Track Record
How signals performed across all stocks →What PLRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -3.1% | 39% | October 7, 2026 |
| Bollinger Band BreakdownActive now | 20 | -1.9% | 45% | October 1, 2026 |
| Bollinger Band Breakout | 21 | -6.4% | 29% | August 18, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -10.0% | 18% | November 28, 2025 |
| Any 20-session window (baseline) | -3.1% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PLRX
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 49
- Website
- pliantrx.com/
Fundamentals
- 1-day range
- $0.9$0.985
- Market cap
- $65.02M
- P/E (trailing)
- —
- P/E (forward)
- -0.70
- EPS (trailing)
- $-2.43
- Dividend yield
- —
- Beta
- 1.34
- Avg. volume
- 428.3K
How Pliant Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2023 annual results
Source: 10-K filed Feb 27, 2024 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Pliant Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PLRXPliant Therapeutics Inc. Common Stock$0.9▼ 7.41%Market cap $65.02MP/E —$0.8838$1.95
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
- BOLDBoundless Bio Inc. Common Stock$2.34▼ 0.43%Market cap $63.80MP/E —$0.9612$3.16
- MNOVMedicinova Inc Common Stock$1.42▼ 2.07%Market cap $66.94MP/E —$1.17$3.9
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.21▼ 6.20%Market cap $62.93MP/E —$1.02$1.91
- RNTXRein Therapeutics Inc. Common Stock$0.59▼ 6.05%Market cap $67.45MP/E —$0.5401$2.18
- CINGCingulate Inc. Common Stock$4.36▼ 0.68%Market cap $68.02MP/E —$3.16$11.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PLRX Pliant Therapeutics Inc. Common Stock | $65.02M | — | $0.9 | ▼ 7.41% | $0.8838$1.95 |
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
| BOLD Boundless Bio Inc. Common Stock | $63.80M | — | $2.34 | ▼ 0.43% | $0.9612$3.16 |
| MNOV Medicinova Inc Common Stock | $66.94M | — | $1.42 | ▼ 2.07% | $1.17$3.9 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $62.93M | — | $1.21 | ▼ 6.20% | $1.02$1.91 |
| RNTX Rein Therapeutics Inc. Common Stock | $67.45M | — | $0.59 | ▼ 6.05% | $0.5401$2.18 |
| CING Cingulate Inc. Common Stock | $68.02M | — | $4.36 | ▼ 0.68% | $3.16$11.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- David Raben · October 1, 2026 · Grant575.0K
- Flavia Borellini · July 9, 2026 · Grant60.0K
- Robert Iannone · July 9, 2026 · Grant60.0K
- Steve E. Krognes · June 11, 2026 · Grant70.0K
- Cline Darren S · June 11, 2026 · Grant70.0K
- Curnutte John T · June 11, 2026 · Grant70.0K
- MCCOURT Thomas A · June 11, 2026 · Grant70.0K
- Hoyoung Huh · June 11, 2026 · Grant70.0K
- CROWELL GAYLE A · June 11, 2026 · Grant70.0K
- Minnie Kuo · April 17, 2026 · Grant40.0K
- Minnie Kuo · April 17, 2026 · Disposition40.0K
- Minnie Kuo · April 17, 2026 · Grant150.0K
- Minnie Kuo · April 17, 2026 · Disposition150.0K
- Keith Lamont Cummings · April 17, 2026 · Grant113.3K
- Bernard Coulie · April 17, 2026 · Grant256.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 48.49M
- Total value held
- $56.71M
- Institutional holders
- 87
- Unknown6.14M
- Unknown3.26M
- Unknown2.97M
- Unknown2.59M
- Unknown2.42M
- Unknown2.34M
- Unknown2.25M
- Unknown1.94M
- Unknown1.85M
- Unknown1.67M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Pliant Therapeutics Names New Chief Medical Officer
Pliant Therapeutics has appointed David Raben, M.D., as its new Chief Medical Officer. This leadership change is a standard corporate update for the company. The stock is currently trading within its 52-week range, with recent technical indicators showing a support rejection near $1.13.
Pliant Therapeutics Names New Chief Medical Officer. Pliant Therapeutics has appointed David Raben, M.D., as its new Chief Medical Officer. This leadership change is a standard corporate update for the company. The stock is currently trading within its 52-week range, with recent technical indicators showing a support rejection near $1.13.